Strategy for earning from Biocon, AU SFB, Sona BLW, and KPIT Technology: Insights from analysts
HSBC has initiated coverage on Biocon with a “Reduce” rating, establishing a target price of ₹300 per share. This assessment comes in light of recent developments concerning the U.S. launch of a biosimilar to Eylea, a key ophthalmic medication. The anticipated launch of Yesafili, Biocon’s own biosimilar, has faced delays due to legal battles, making ...